PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. - Wikidata - wikimedia - TriplyDB

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

http://www.wikidata.org/entity/Q30416701

about

The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways Therapeutic targeting of cancers with loss of PTEN function.Personalized characterization of diseases using sample-specific networks Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity.Mutant p53 gain-of-function in cancer.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.Evolutionary pathways in BRCA1-associated breast tumors.PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation Applications of emerging molecular technologies in glioblastoma multiforme Targeting prostate cancer based on signal transduction and cell cycle pathways.Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression.Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.TP53 mutants in the tower of babel of cancer progression.PI3K/Akt-mediated regulation of p53 in cancer.Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status.HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma.PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer.The p53 Pathway in Glioblastoma

P2860

Q24306770-86F1CC1C-BF25-4894-A0D8-65C7B309EF21 Q26767396-37BA6841-7D7A-430D-86BD-2E3B24CBB5C0 Q27852764-75D9AF78-941A-4C42-99A1-6DF3DBE72FFC Q28586781-B455A421-55CF-48DD-A8FA-A8E63C29E72E Q30405446-0145F0F1-1F84-43B3-994A-C23C68A51FB3 Q30417988-95DB5BEB-4CEB-48A9-B205-4504EF075747 Q30422676-84F338BA-9A95-4F7D-9899-FA071AC6D783 Q30428363-43832642-3BB1-47FE-BD06-DB2D551D00A8 Q30428366-803889BA-1E3B-4904-AF5D-756BF1357F7F Q30432036-74423DC7-2413-4E1C-9617-66347250BD7F Q30434616-45A86C45-3200-49B0-84B4-99576364E4F9 Q30434675-9E6DF939-D2C0-4028-AE30-C67E9477E92E Q30437740-410EDC74-FEB0-4E4D-A016-7FF7687518E2 Q33574529-22FBC703-A09D-44D6-A6A2-EA2D0A956F3C Q33687048-AC6CCA48-EFA0-426A-8CE5-77406B4B5ECE Q34103978-40321958-A468-4A56-AF8A-8B24D6BE162D Q34133079-059A4662-A399-4383-BA17-938D0F64349E Q34277174-04A610D8-5586-47E7-AF23-5520E22DDAB5 Q34514602-A59932C1-73AC-4450-BC25-A42403554505 Q34965421-54BD8F9C-C587-4BA3-8BD3-9733C7FD813F Q36880907-7D67D8FB-CC11-427C-B617-DEB02B78E1E3 Q36941509-622674A2-2875-471A-A7FE-E88249F65A06 Q36965370-E96C24E2-14D8-49F0-872E-94BE8A002194 Q36995054-F76DB911-6947-469E-81F1-C92A6C2CD052 Q37158722-E0DA515E-2DDE-4205-94D8-3F117B06CCE3 Q37698905-9074C815-B62C-46E0-8DFC-395D5A9866A4 Q38112074-9D673C4E-5ED8-4437-B48D-40F6D5B5BD33 Q38180665-51560EDD-B385-4EFA-BB33-C5AD18EBD7AC Q38238609-34E1FFD8-C19F-4E55-A97A-055B63151034 Q38605143-1B8FAAAD-8A7F-4D46-8675-0230ED170864 Q38899532-096EA089-9B1D-4376-9F17-B9E013337C41 Q39005896-6B699950-83D1-4D03-8949-80CC6421DC3B Q39027066-A22F9E68-E302-4489-AFED-0BAACA3854C0 Q39307665-D0215621-34DE-4F4B-92E4-A2E4393E0B3A Q39557390-FF293201-6C2F-435D-A5ED-93BA5F4725AC Q39740608-6CEA5009-5F8D-4D50-9CF5-82AD7D2C7395 Q39844741-68C501E9-C85B-4682-A7C7-B8AE9AB4D448 Q42921293-B26B5E7B-6F70-4E50-A941-3884E0BBEC7D Q52584348-629F79BD-320B-45D6-A46F-E4229B9EC947 Q57162865-BD0DC5B0-1505-4040-843C-9F050C8520B4

P2860

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

http://www.wikidata.org/entity/Q30416701

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

@ast

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

@en

type

label

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

@ast

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

@en

prefLabel

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

@ast

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

@en

P1433

Q30416701-BACDDC8D-4CDC-4985-9FF8-5D00437AF32E

P1476

Q30416701-FCF59FF4-CE9A-480C-8B6D-DB789FA58D75

P2093

Q30416701-1F8FBFDF-B13E-41F4-9BC6-E96B3C590B20

Q30416701-321C9A62-DB99-4E03-BCE1-9FFE98840F80

Q30416701-4442DFAC-BFA3-4C17-AF34-B47E3C21D7D0

Q30416701-50CA8121-C8E6-4CEC-A542-6C0EDF63D83D

Q30416701-569DAA4A-F1A9-4026-A757-B67661AAEC9F

Q30416701-63447A39-2F65-47E3-AB1B-B3B2615C93E6

Q30416701-A88853A4-898D-43F3-9065-74BF100B85AD

Q30416701-B117F376-E627-49E6-BAB4-6178C1C2B5A8

Q30416701-B8989F77-6DB4-496C-B3E4-F405D59B9377

Q30416701-C93D56E4-88AA-463E-BAC4-F2227E424843

P2860

Q30416701-07F79F18-5DAD-4EDB-AFC9-468391798CB6

Q30416701-192AC4B9-D2D1-46EC-A44A-74C4ADEE670A

Q30416701-1E56020F-0080-4212-8718-F4D8392BA0A3

Q30416701-2E68B711-1DB6-4BD7-829C-A85A172182CE

Q30416701-323C94F2-A895-45A5-961D-D087BBEF86A7

Q30416701-32AB7B35-EAB0-4B39-BAC2-2C7686D9C1C3

Q30416701-373AF53C-DEC1-49AE-A27E-27B0BE84DB7E

Q30416701-3C85806B-60E1-4B46-8A39-BB342719244D

Q30416701-3E6D0A46-D083-462A-8788-EEA6CD16D424

Q30416701-4D997C9C-30A6-4194-803B-761173BC67FE

P304

Q30416701-9ABB2CDC-1D72-428E-866F-1C64FB0F786D

P31

Q30416701-AC8BC911-38BA-4002-B1C7-33E3E5D56C79

P356

Q30416701-2F80093F-EE1B-4562-9722-A2B84760D57C

P407

Q30416701-9C6C5F71-5960-4C5B-92A3-B14B63262D9C

P433

Q30416701-9604EC37-9B0A-4E4E-920D-C2F62DF16C4C

P478

Q30416701-EB7A03FD-ED6F-4419-A45C-6F2E0466058A

P577

Q30416701-38C16C97-A4DB-4A9D-9720-D980B437F0B2

P5875

Q30416701-C869017C-9CE2-4D76-B11B-C7ACEE43E64F

P698

Q30416701-F52373F6-DEF8-4DA9-B050-C1DBEA4F2DCE

P932

Q30416701-D78A80CC-7F92-4AEC-B0A8-13359FAC3A73

P356

0008-5472.CAN-07-1963

P1433

Cancer Research

P1476

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

@en

P2093

Bachchu Lal

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

Elizabeth Johnson

http://www.w3.org/2001/XMLSchema#string

Fadila Guessous

http://www.w3.org/2001/XMLSchema#string

Isa Hussaini

http://www.w3.org/2001/XMLSchema#string

John Laterra

http://www.w3.org/2001/XMLSchema#string

Lauren Fuller

http://www.w3.org/2001/XMLSchema#string

Manish Kumar

http://www.w3.org/2001/XMLSchema#string

Opeyemi Ibidapo

http://www.w3.org/2001/XMLSchema#string

Roger Abounader

http://www.w3.org/2001/XMLSchema#string

P2860

A simplified system for generating recombinant adenoviruses

Surfing the p53 network

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

Regulation of PTEN transcription by p53

Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

Pten signaling in gliomas.

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Transcriptional activities of mutant p53: when mutations are more than a loss.

P304

1723-1731

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-07-1963

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5512197

http://www.w3.org/2001/XMLSchema#string

P698

18339852

http://www.w3.org/2001/XMLSchema#string

P932

3813002

http://www.w3.org/2001/XMLSchema#string